COVID-19 Pandemic Leads to Decrease in GI Patient Encounters and New Diagnoses of GI Cancers and Procedures
Investigators analyzed the impact of the COVID-19 pandemic on number of GI procedures performed and new cancer diagnoses.
Emerging Treatments
Faster Clinical Improvement With Remdesivir Among Minority Groups With COVID-19
Study authors compared data of minority patients with COVID-19 to assess whether remdesivir alone or with steroids resulted in clinical improvement.
Convalescent Plasma With Higher Antibodies Associated With Lower COVID-19 Mortality Risk
Study authors conducted a retrospective study to determine the anti-SARS-CoV-2 IgG antibody levels in convalescent plasma used to treat hospitalized patients with COVID-19.
American Indians/Alaska Natives Have Elevated COVID-19 Mortality
American Indians/Alaska Natives (AI/ANs) have disproportionate COVID-19 mortality rates.
Considerations for Hydroxychloroquine Use in Patients With Diabetes
Careful consideration should be taken before using hydroxychloroquine in patients with diabetes, particularly in the context of COVID-19.
Merck Collaborating on Novel COVID-19 Vaccine, Oral Antiviral
The vaccine candidate is currently in preclinical development with clinical studies expected to begin later this year.
High Dose IVIG to Be Investigated for Severe COVID-19 in Phase 3 Trial
The FDA has approved Octapharma’s Investigational New Drug Application allowing the Company to initiate a phase 3 trial of Octagam® (immune globulin intravenous [human]) in patients with COVID-19 with severe disease progression.
Hydroxychloroquine With or Without Azythromycin for COVID-19 Treatment Associated With Increased Risk for QTc Prolongation
Patients treated with hydroxychloroquine alone or in combination with azithromycin for pneumonia associated with COVID-19 were found to be at increased risk for corrected QT interval prolongation.
Generic Version of Antifungal Drug Mycamine Now Available
Fresenius Kabi announced the launch of Micafungin for Injection, a generic version of Mycamine (micafungin for injection; Astellas Pharma).
Microbiome-Based Therapy Looks Promising for Recurrent C Difficile Infection
“These positive preliminary findings represent a major step forward towards bringing an innovative, non-antibiotic option to patients that may help restore their gut microbiome,” said Per Falk, Ferring’s President and Chief Science Officer.
- Loading...
Loading...
Next post in Clostridioides Difficile
Loading... 
Loading...